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ABSTRACT
We have identified the irreversible protein modification S-(2-succino)cysteine, a
product of the Kreb’s cycle intermediate fumarate reacting with the thiol group of
cysteine (Cys) residues, also termed succination. Succination is increased in adipose
tissue of diabetic mice in vivo and in adipocytes matured in high glucose medium (25
mM) in vitro. Selenocysteine (Sec) is a less common but highly conserved amino acid
that has major functions in redox chemistry. Sec possesses a lower pKa (~5.4) and is
much more reactive in comparison to Cys. This project aimed to determine if succination
occurred on Sec residues in two selenoproteins that play roles of maintaining intracellular
redox environments and contain Sec in their active sites, thioredoxin reductase (TrxR)
and glutathione peroxidase (GPx). We hypothesized that increased fumarate levels will
lead to the succination of Sec and causing decreased enzymatic activity for each enzyme.
Two cellular models were used with elevated fumarate levels: (1) 3T3-L1
adipocytes matured in high glucose medium (25 mM) to mimic diabetic conditions and
(2) 3T3-L1 fibroblasts where fumarase was knocked-down (Fh k/d) to mimic fumarase
deficient cancers. As a positive control to demonstrate the ability to succinate TrxR in
vitro, recombinant TrxR1 was incubated with the reactive fumarate ester, dimethyl
fumarate (DMF). After analysis, a ~56% reduction in activity was detected due to
succination of an active site residue, which was confirmed by mass spectrometric
analyses.
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Unexpectedly, TrxR activity was found to be significantly increased in 3T3-L1
adipocytes matured in 25 mM glucose compared to 5 mM glucose, despite no changes in
protein levels. No statistically significant changes in TrxR activity were found in Fh k/d
3T3-L1 fibroblasts compared to controls. GPx activity was found to be significantly
reduced in 3T3-L1 adipocytes matured in high glucose with no changes in levels of GPx
protein. GPx activity was also analyzed in Fh k/d 3T3-L1 fibroblasts, however no
significant changes were detected.
Overall, the results demonstrate that TrxR can be modified readily by reactive
fumarate esters, leading to decreased enzymatic activity. However, endogenously
produced fumarate does not appear to significantly contribute to TrxR or GPx
modification in the models studied.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Succination of Proteins
The amino acid cysteine (Cys) plays unique biological roles in nature due to its
chemical structure. Cysteine contains a thiol group with a pKa ~9.5 (1) when exposed on
the surface of a protein, but its pKa can be as low as ~3-4 when located within the active
site of an enzyme (2). Therefore the thiol group is readily deprotonated in physiological
conditions and can be considered one of the most reactive residues found in peptides (3).
This reactivity makes cysteine a strong nucleophile and the thiolate (S-) is susceptible to
increased oxidation to the reversible sulfenic acid (SOH) (4), or further to the irreversible
sulfinic (S(O)2H) and sulfonic acids (S(O)3H) (5). Sacrificial thiol oxidation is known to
play an important role in the cellular response to oxidative stress, and partially oxidized
thiols are often functionally regenerated by the glutathione system.
Alterations in cellular metabolism may lead to increases in oxidizing
intermediates, but other metabolic intermediates are also capable of chemically
modifying cysteine thiolates. Recently, the modification of cysteine residues in proteins
by the Kreb’s cycle intermediate fumarate has been described. In the case of this
modification, known as protein succination, fumarate undergoes a Michael addition
reaction to form a thioether bond with the thiol group of cysteine yielding a product
termed S-(2-succino)cysteine (2SC) (6, 7) (Figure 1.1). Protein succination is an
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irreversible, non-enzymatic post-translational modification of proteins that may result in
alteration of the protein structure or function. The 2SC modification has been detected on
over 50 proteins expressed by mouse adipocytes (6), but has also been detected in human
plasma albumin, consisting of 3.5% of the total protein (7), in skin collagen and skeletal
muscle proteins (2). Reduced functionality following protein succination has been
demonstrated for cytosolic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
mitochondrial aconitase, with both exhibiting decreased enzymatic activity (8, 9).
GAPDH is a glycolytic enzyme that, when inhibited during hyperglycemic conditions, is
linked to the development of diabetic complications such as vascular endothelial damage
(10). Aconitase is a Kreb’s cycle enzyme responsible for isomerization of citrate to
isocitrate and its impaired activity results in a disruption in mitochondrial metabolism (9).
The adipocyte hormone adiponectin circulates in plasma as high molecular weight
oligomers and stimulates fatty-acid oxidation in muscle and in the liver (11). Adiponectin
is also a target of succination and this inhibits its oligomerization, preventing its secretion
into plasma where it can circulate to its target receptors throughout the body (12). This
fact is significant considering that high molecular weight forms of adiponectin are
decreased in the plasma of Type 2 diabetics.
In the adipocyte, protein succination is a direct effect of mitochondrial stress
caused by elevated extracellular glucose levels when cellular metabolism is increased.
These conditions lead to an increase in ATP/ADP ratios and an accumulation of ATP.
This accumulation inhibits the mitochondrial electron transport chain through respiratory
control, increasing the mitochondrial membrane potential (Δψm) and NADH/NAD+ ratio,
leading to an accumulation of fumarate due to the inhibition of NAD+–dependent Kreb’s
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cycle enzymes (13) (Figure 1.2). Increased levels of succinated proteins have been
demonstrated in both 3T3-L1 adipocytes matured in high glucose medium (30 mM)
versus normal glucose medium (5 mM), and in the adipose tissue of diabetic db/db mice
(13, 14). Beyond the adipocyte, increased succination has also been detected in hereditary
leiomyomatosis and renal cell cancer (HLRCC) where the enzyme fumarase, responsible
for converting fumarate to malate, is deficient or mutated, leading to a pronounced
increase in succination in these tumors (15). In fact, the immunohistochemical detection
of succinated proteins is used clinically as a biomarker for fumarase deficiency (6, 16, 17,
18). Increased levels of protein succination have most recently been described in a
mitochondrial encephalopathy associated with a defect in mitochondrial oxidative
phosphorylation, where increased succination of select proteins may play a role in
defective neuronal function (19).
1.2 Selenocysteines
In general, there are twenty abundant amino acids found in nature. However a less
common, but highly conserved amino acid, selenocysteine (Sec), plays a critical role in a
range of cellular functions. Often coined the “21st amino acid” (20), Sec has a similar
chemical structure to the more common amino acid cysteine, with the exception of a
selenium atom in place of sulfur. The two amino acids have different chemical properties,
as selenocysteine has a much lower pKa value (~5.4) compared to cysteine (~9.5) (21).
This lower pKa of Sec results in the selenol group (SeH) being deprotonated in
physiological pH ranges (6.5-7.5), yielding the selenolate (Se-) form, and thus Sec is
more reactive than Cys (22). Sec is inherently a strong nucleophile, and therefore is often
found in the active site of enzymes that play a role in redox reactions.
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Selenoproteins are defined as proteins that contain one or more Sec in their
sequence. During protein translation, Sec is encoded by the UGA mRNA codon, which
under normal circumstances will terminate protein synthesis (23). However the mRNAs
for selenoproteins contain a selenocysteine insertion sequence (SECIS), a stem-loop
structure that resides downstream from the UGA codon and allows the Sec-specific
translation machinery to associate with the ribosome (20). Without the SECIS, the protein
will be prematurely truncated and no Sec will be incorporated.
Selenoproteins exist in all three domains of life and currently over 50 different
families of these proteins have been identified (24). Humans contain 25 known genes that
encode selenoproteins (23), having functions from redox signaling, protection from
reactive oxygen species (ROS), protein folding and thyroid hormone metabolism. The
wide range of biological functions that selenoproteins possess, particularly in redox
biology, is dependent upon the chemical properties of selenocysteine (24). These proteins
are widely distributed throughout the human body, some being ubiquitous while others
are tissue and organelle specific (25). Many selenoproteins are proposed to be essential
for normal brain development and therefore highly expressed in nervous system, and
deficits in some selenoproteins have been linked to an assortment of neurological
disorders in mice (26, 27, 28).
1.3 Oxidative Stress in Disease
Reactive oxygen species (ROS) can arise in the cell from mitochondrial oxidative
metabolism, or from cellular responses to xenobiotics, cytokines or microbial invasion
(29). The most abundant forms of these species found in the cell are hydrogen peroxide

4

(H2O2) or superoxide (O2-). Under physiological concentrations, ROS may function as
regulators of intracellular signaling pathways, primarily through the oxidative
modification of specific cysteine residues on target proteins (30). In some cases, ROS
have significant physiological roles, for instance they are involved in the regulation of
cellular processes such as inflammation through modification of Nuclear Factor kappa B
thiol groups (31, 32), and the response to growth factor (GF) stimulation (30).
Maintaining an appropriate concentration of ROS is critical for normal cellular function,
and oxidant mediated stress may develop when the production of ROS increases.
Therefore antioxidant systems such as the thioredoxin and glutathione systems must also
be properly regulated to maintain homeostatic environments. The abundance of Sec
containing selenoproteins in the antioxidant response system emphasizes the roles of
these proteins in dealing with the balance of intracellular ROS.
Oxidative stress is defined as a disruption in the balance between the production
of ROS and antioxidant defenses (33). Therefore, oxidative stress can arise when there is
an increase in the amount of ROS produced and/or a decrease in the activity or levels of
antioxidants (34). In diseases such as diabetes mellitus, hyperglycemic conditions lead to
a pronounced increase in the production of ROS, disrupting the physiological balance
between oxidants and antioxidants, ultimately causing oxidative stress and cellular
damage (35). Adipocytes exposed to hyperglycemic conditions in vitro and in vivo are
associated with increased levels of ROS production, a pronounced inflammatory response
and insulin resistance (36). Insulin resistance in skeletal muscle has been linked to
persistently oxidized redox environments caused by increased mitochondrial ROS
production during high fat diet feeding (37). The thioredoxin system, specifically
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thioredoxin reductase 1 (TrxR1), has been shown to be critical for neutralizing glucosederived H2O2 under high glucose conditions in vitro (38).
1.4 Thioredoxin Reductase
The thioredoxin system, consisting of thioredoxin (Trx), thioredoxin reductase
(TrxR) and nicotinamide adenine dinucleotide phosphate (NADPH), is ubiquitous in all
cellular organisms (39). This crucial system provides redox regulation of protein function
and signaling through its action of reducing cellular thiols (39). Wide regulation of gene
expression through redox control of transcription factors constitutes one of the major
roles of the thioredoxin system (40). Trx, in its reduced form, serves as a hydrogen donor
to catalyze the reduction of disulfide bonds found in the redox-sensitive proteins such as
apoptosis signal-regulated kinase 1 (ASK1), thioredoxin interacting protein (Txnip),
phosphatase and tensin homolog (PTEN), and other targets that function in the
modulation of cellular processes such as inflammation, metabolism, development,
proliferation and migration (41). Through maintaining intracellular redox environments,
this system also provides a major defense against oxidative stress and the prevention of
apoptosis (42).
Thioredoxin reductase is also a critical part of the thioredoxin system as its
primary function is to maintain the reduced form of Trx through its catalytic cycle (39)
(Figure 1.3). TrxR is a monomeric selenoprotein, with the active site Sec residue located
penultimate to the C-terminal glycine of the protein (40, 43). The N-terminal region of
TrxR is an FAD (flavin adenine dinucleotide)-binding domain, which is responsible for
the transfer of reducing equivalents in the catalytic cycle (44). During TrxR catalysis,
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electrons are transferred from NADPH to the TrxR-bound FAD, which subsequently
transfers electrons to reduce the active site Cys-Sec selenylsulfide bond (40, 44). The
importance of the active site Sec during the TrxR catalytic cycle is highlighted when this
residue is substituted with Cys, as this does not result in the formation of an active site
disulfide bond and the Cys mutant enzyme shows almost no activity (38, 40, 43). Three
mammalian forms of TrxR have been identified: the cytosolic TrxR1, the mitochondrial
TrxR2, and the testis-specific TrxR3 (40), with the most abundant isoforms being TrxR1
and TrxR2.
In its reduced form, TrxR has the ability to directly reduce other substrates inside
the cell, both proteins and small molecules such as vitamin K, alloxan and lipoic acid
(40). As previously mentioned Sec has a pKa ~5.4 and will be ionized under
physiological pH ranges. The reactivity of Sec and its exposed location on TrxR leaves
the enzyme susceptible to modification at the active site, rendering it incapable of
reductase activity. Modification of TrxR has previously been demonstrated in vitro by
exogenous electrophiles where the Sec residue and several other Cys residues were
irreversibly modified (45, 46).
1.5 Glutathione Peroxidase
The glutathione system consists of the enzymes glutathione (GSH), glutathione
reductase (GR), glutathione peroxidase (GPx), and the hydrogen donor NADPH. GSH
contains a thiol group in the form of a cysteine residue and plays a major role in the
cellular antioxidant response through either the direct reduction of reactive
oxygen/nitrogen species (ROS/RNS), or by acting as a cofactor for other enzymes (47).
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The reduced form of glutathione (GSH) becomes oxidized to GSSG following the
reduction of cellular proteins or the neutralization of hydrogen peroxide (H2O2). This
system is considered to be the back-up for the thioredoxin system that also serves to
protect from oxidative damage, as previously described.
Glutathione peroxidase is a key selenoprotein in this system’s regulation of redox
environments, containing a Sec residue in its active site. The properties of Sec allow GPx
to function as a strong reducing agent and it is involved in the reduction of hydrogen
peroxides, organic hydroperoxides (e.g. cumene hydroperoxide) and lipid peroxides from
fatty acid radicals (24). In the catalytic cycle for the neutralization of H2O2, the selenolate
(Se-) group reacts with H2O2 to form selenic acid (SeOH), which is subsequently reduced
back to selenol (SeH) by 2 GSH, yielding GSSG and water (48, 49, 50, 51) (Figure 1.4).
GSSG is reduced by the enzyme glutathione reductase through the transfer of hydrogen
from NADPH, recycling the system and allowing it to repeat its redox activity. The first
isoform of GPx (GPx1) was the first human selenoenzyme to be discovered (52). There
are a total of 8 identified isoforms of this enzyme; however GPx1 and GPx4 are the most
abundant and ubiquitously expressed isoforms in the cell (51).
The neutralization of H2O2 allows GPx1 to maintain the balance between the
required concentrations of ROS that play physiological roles and the higher
concentrations that lead to cellular damage (53). GPx4 has a more specialized function of
protection of membranes from lipid peroxidation directly by hydroperoxides found inside
of membranes; a function that enables this isoform of the enzyme to be involved in the
attenuation of oxidative stress-induced apoptosis (24, 51). Alterations in the levels or the
activity of GPx can lead to abnormal levels of intracellular ROS and these changes have
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been linked to cardiovascular disease and diabetes (53). There are no known specific
inhibitors of GPx, however oxidative modification of thiols and selenols represents the
most characterized modification of this enzyme (53).
1.6 Research Hypothesis and Aims
Due to the chemical nature of selenocysteine and its predicted higher reactivity at
physiological pH when compared to cysteine, I hypothesize that Sec is susceptible to
succination when fumarate levels are elevated. Preliminary experiments in our lab have
demonstrated that free amino acid Sec can be succinated by fumarate following in vitro
incubation (unpublished data). Although this in vitro experiment does not account for the
variable factors that can affect the reactivity of a protein, it provides a foundation for the
aims of this thesis further described in the hypothesis. The fact that lower pKa residues in
proteins may be more vulnerable to this modification has been demonstrated following
the identification of succination of Parkinson disease protein 7 (Park7) on an active site
Cys that possesses an unusually low pKa (~5.4) (16). In this thesis I will examine the
succination of the selenoproteins thioredoxin reductase and glutathione peroxidase. Due
to the presence of Sec in the active site of these enzymes, irreversible modification of this
residue is predicted to inhibit the enzyme. As a consequence, the resulting decreased
activity may leave the cell more vulnerable to redox active species. The exposed location
of Sec on the C-terminus of TrxR makes this protein particularly interesting as a
candidate for succination.
Two different cell culture models will be used in this investigation; (1) adipocytes
matured in high glucose medium to model diabetic conditions (versus controls in normal
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glucose medium), or (2) fumarase knockdown in fibroblasts to model fumarase-deficient
cancers, creating a model of enhanced succination. I will specifically examine the activity
and protein levels of thioredoxin reductase and glutathione peroxidase in both of these
cell models of elevated endogenous fumarate.
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Figure 1.1: Protein succination reaction mechanism. Fumarate undergoes a Michael
addition reaction to form a thioether bond with the thiol group of cysteine residues,
yielding a product termed S-(2-succino)cysteine (2SC). Protein succination is an
irreversible, non-enzymatic post-translational modification of proteins that may result in
alteration of the protein structure or function.
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Figure 1.2: Glucotoxicity driven mitochondrial stress increases protein succination.
In the adipocyte, protein succination is a direct effect of mitochondrial stress caused by
elevated extracellular glucose levels when cellular metabolism is increased. These
conditions lead to an increase in ATP/ADP ratios and an accumulation of ATP. This
accumulation inhibits the mitochondrial electron transport chain through respiratory
control, and increasing the mitochondrial membrane potential (Δψm) and NADH/NAD+
ratio, leading to an accumulation of fumarate due to the inhibition of NAD+–dependent
Kreb’s cycle enzymes. Elevated levels of intracellular fumarate lead to the succination of
protein thiols.
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Figure 1.3: The Thioredoxin system. The thioredoxin system consists of thioredoxin
(Trx), thioredoxin reductase (TrxR) and the hydrogen donor nicotinamide adenine
dinucleotide phosphate (NADPH). This ubiquitous system provides redox regulation of
protein function and signaling through its action of reducing cellular thiols. TrxR is a
selenoprotein containing a selenocysteine (Sec) in its active site, and it is responsible for
reducing the disulfide bond in Trx.
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Figure 1.4: The Glutathione system. The glutathione system consists of the enzymes
glutathione (GSH), glutathione reductase (GR), glutathione peroxidase (GPx), and the
hydrogen donor nicotinamide adenine dinucleotide phosphate (NADPH). GSH contains a
thiol group in the form of a cysteine residue and plays a major role in the cellular
antioxidant response through either the direct reduction of reactive oxygen/nitrogen
species (ROS/RNS), or by acting as a cofactor for other enzymes such as GPx. GPx is a
scavenging selenoprotein containing a selenocysteine (Sec) in its active site, and it plays
vital protective roles inside the cell through its function of reducing damaging species
such as hydrogen peroxide (H2O2), organic peroxides and lipid peroxides.
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CHAPTER 2
THE EFFECTS OF DIMETHYL FUMARATE (DMF) AND FUMARATE
ON THIOREDOXIN REDUCTASE 1

2.1 Introduction
Multiple sclerosis (MS) is an inflammatory disease that results in the
demyelination and loss of axons in the central nervous system (CNS) (54). The disease
affects approximately one in every thousand Americans; with females being affected
twice as often as males (55, 56). Tecfidera® is a recently approved drug used to treat
relapsing-remitting MS (RRMS), a form of the disease characterized by attacks of
worsening neurological function, followed by partial or complete recovery periods (57).
The primary active component of Tecfidera® is dimethyl fumarate (DMF), a more
reactive fumarate ester that is more easily absorbed and has better bioavailability than
fumarate when administered orally (58, 59). DMF is also considered both safe and
effective in the treatment of psoriasis, where it has been approved for use in Europe for
over a decade (60). After ingestion, intracellular esterases rapidly hydrolyze DMF to the
bioactive metabolite monomethyl fumarate (MMF) (58, 61). The efficacy of DMF
treatment was tested in two randomized, double-blind, placebo-controlled clinical trials
with RRMS patients and resulted in significantly reduced lesions (permanent axonal
damage/loss), confirmed by magnetic resonance imaging (MRI) in those individuals who
received the drug (58, 62, 63, 64, 65).
15

DMF promotes therapeutic cytoprotection in treating RRMS through the
activation of the nuclear factor (erythyroid-derived)-like-2 (Nrf2) pathway, a
transcription factor that induces the upregulation of antioxidant proteins (66, 67). After
DMF is metabolized to MMF, it reacts with a Cys residue on the Nrf2-bound Kelch-like
ECH-associated protein 1 (Keap1), leading to the stabilization of Nrf2 and its
translocation to the nucleus where it binds the antioxidant response element (ARE) and
promotes the transcription of its target antioxidant genes such as gammaglutamylcysteine synthetase (synthesizes glutathione (GSH)) and thioredoxin reductase 1
(TrxR1) (68, 69). DMF/MMF readily reacts with the cysteine thiol of GSH, one of the
first described targets of the drug, causing levels to be depleted and strongly inducing the
anti-inflammatory stress protein heme oxygenase 1 (HO-1) (70, 71). DMF also
suppresses pro-inflammatory genes by inhibiting nuclear factor kappa B, and combined
with the anti-oxidative targets of Nrf2 activation, these responses are believed to slow the
demyelination and neurodegeneration associated with MS by causing a decrease in
circulating T cells and CD4+ cells involved in inflammation (62, 66, 72, 73).
Despite the efficacy of DMF treatment in MS patients and the increased quality of
life observed after clinical trials, the drug is also known to cause side effects such as
gastrointestinal discomfort, nausea and flushing severe enough for ~10% of patients to
discontinue use (73). The presence of these side effects and the inherent reactivity of
fumarate esters would suggest that there are other cellular targets that are also being
modified. Our laboratory has recently confirmed that DMF and its metabolite MMF
result in the succination of multiple proteins in 3T3-L1 mouse adipocytes treated with
DMF (74).

Pronounced increases in succinated Cys residues were also identified
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following immunoblotting and LC-MS/MS analysis of porcine tubulin treated with DMF,
and increased succination prevented its polymerization (75).
As previously mentioned, the Cys-Sec residues in the active site of TrxR reside on
the exposed C-terminal region of the protein (Figure 2.1), suggesting this region of TrxR
may be a likely target of DMF modification. In this study I investigated the succination of
TrxR by DMF, hypothesizing that (1) I would demonstrate the vulnerability of this
enzyme’s active site to modification and, (2) identify a novel protein modified by DMF.
These studies would also determine if the same active site residues might also be
susceptible to succination by the less reactive but endogenously produced metabolite
fumarate.
2.2 Results
To determine the effects of DMF on TrxR activity in vitro, rat recombinant
thioredoxin reductase 1 (TrxR1) protein was reduced with NADPH prior to incubations
with 0, 5, 50 and 100 µM DMF for 1 hour at room temperature. The pre-reduction step of
TrxR by NADPH is necessary since the active site Cys-Sec forms a selenylsulfide bond
(Figure 1.3) (46), needs to be reduced so that the selenolate (Se-) can react with
electrophiles. The enzymatic activity was measured following the reduction of 5 mM
5,5’-dithio-bis(2-dinitrobenzoic acid) (DTNB) and expressed as the rate of molar
nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mg protein (mean
 S.E.M) (Figure 2.2). Incubations with 50 and 100 µM DMF exhibited activities (mean
 S.E.M.) of 9.98  0.41 and 5.71  0.24 µmol/min/mg respectively, compared to the
control activity of 13.74  0.54 µmol/min/mg. These activities were statistically
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significant decreases compared to the control; a ~27% average decrease in activity for the
50 µM group and ~56% average decrease in the 100 µM group.
Proteomic analysis using high-resolution mass spectrometry (MS) was performed
on rat recombinant TrxR1 incubated in 100 µM DMF for 1 hour at room temperature to
confirm succination and also identify specific succinated residues. The protein was
digested with trypsin (cleaves after lysine and arginine residues), generating a series of
peptides that were distinguished based on the mass/charge ratio (m/z). The potential
alteration in peptide mass due to the addition of MMF or DMF protein adducts on Cys or
Sec residues was then considered. This analysis revealed that DMF modified 3 of the 13
Cys residues on the protein; Cys177 was modified by MMF, Cys189 was modified by
either MMF or DMF, and Cys475 was modified by MMF. All of these cysteine
containing peptides were detected with increases in mass of 130 Da (mass of MMF) or
144 Da (mass of DMF). The masses detected were consistent with the Michael addition
of free cysteine sulfhydryl group across the double bond of MMF or DMF. Despite the
immediate identification of several succinated cysteine containing peptides, I was
particularly interested in the N-terminal peptide containing the Sec residue. Further
MS/MS analysis and fragmentation of the specific mass attributed to the terminal peptide
sequence (SGGDILQSGCUG) confirmed MMF modification of this peptide. However,
while the ion fragments detected confirmed the identity of the succinated peptide, they
did not allow the assignment of the specific succinated site, i.e. it was either one of active
site residues Cys497 or U498 (Table 2.1). An MS/MS spectrum of the peptide
([MH+3]3+, 458.50 Daltons) (Figure 2.3) shows the 5 fragments of the parent ion
identified and the corresponding masses, confirming sequence identity. The fragments
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detected are b ions, indicating they were generated from the fragmentation at the Nterminus of the peptide. The data confirms that the active site Sec containing peptide was
succinated, amongst additional succinated sites, in association with the reduction in
enzymatic activity.
After successfully demonstrating reduced activity of TrxR1 in vitro by
succination of active site residues after DMF treatment, the effects of fumarate on the
enzymatic activity were investigated. Recombinant rat TrxR1 protein was pre-reduced
with NADPH prior to incubations with 0, 10, 50 or 100 mM fumarate for 6 hours at room
temperature. TrxR activity was measured and expressed as the rate of molar NADPH
oxidation per mg protein (mean  S.E.M). However there was no detectable reduction in
enzymatic activity with any fumarate concentration compared to the control group
(Figure 2.4). Additional experiments were performed at a range of different incubation
times and temperatures; however detectable decreases in TrxR activity could not be
established (data not shown).
TrxR activity and protein levels were next investigated in the lysates of N1E-115
neuronal cells after treatment with DMF. The cells were treated with a 100 µM DMF for
either 3 hours or 24 hours prior to harvesting protein, and compared to a control group
where no DMF was added. However, reliable data for TrxR activity could not be
generated for this model. The TrxR activity assay utilizes a TrxR-specific inhibitor,
where the total thiol-reducing activity (samples without inhibitor) is measured in parallel
with the non-TrxR thiol reducing activity (samples containing TrxR inhibitor). TrxR
activity can be calculated by subtracting the non-TrxR activity (inhibitor present) from
the total thiol-reducing activity (inhibitor not present). Two separate attempts at this
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assay were performed however samples containing the TrxR inhibitor consistently
displayed higher activities than the non-inhibited samples, resulting in negative values for
TrxR activity. In the absence of TrxR activity, the total protein levels of TrxR1 and
TrxR2 were analyzed in the control vs. 3 hour DMF vs. 24 hour DMF by
immunoblotting, however no apparent changes in the levels of the cytoplasmic TrxR1
(Figure 2.5, TrxR1 panel, lanes 1-5 vs. lanes 6-10 vs. lanes 11-15) or mitochondrial
TrxR2 (Figure 2.5, TrxR2 panel) were detected between the three groups. The levels of
-tubulin (DM1A) were used to demonstrate equal protein loading (Figure 2.5, DM1A
panel).
2.3 Discussion
The ability of DMF to modify TrxR and significantly reduce its activity was
confirmed through enzymatic activity assays and MS proteomic analysis. This is the first
time that succination has been identified as a modification of this enzyme and these data
provide new information on the mechanism of action of this drug. The reactivity of DMF
is also highlighted by these findings, as the protein was modified with reduced activity
after only 1 hour incubation at room temperature, and these results served as proof of
concept for the susceptibility of TrxR to succination. Although MS/MS analysis could
not confirm succination of the particular succinated residue in the active site (Cys497 or
Sec498, Table 2.1), the observed decrease in enzymatic activity was most likely due to
the modification of either active site residue by DMF, since they are both critical for the
overall reaction mechanism (Figure 1.3). One might postulate that the much higher
reactivity of Sec compared to Cys would cause Sec to be more favorably modified.
Despite the uncertainty surround the particular active site residue was modified by DMF,
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the data clearly demonstrates that a reduction in enzymatic activity could be observed
after modification of either of these residues. Future experiments may be able to confirm
the precise location of modification through further MS analysis to determine if Sec
specifically has greater reactivity with this electrophile.
Although succination and decreased TrxR activity was observed in vitro for
recombinant protein treated with DMF, the inability to successfully measure TrxR
activity in a cell treated with DMF does not allow further conclusions to be drawn
regarding DMF effects on intracellular TrxR. The TrxR activity assay utilizes a TrxR
inhibitor (sodium aurothiomalate) that allows other non-TrxR enzymatic reductions of
DTNB to be subtracted from the total activity measured. Two activity experiments were
performed on N1E-115 cell samples where groups with the inhibitor present abnormally
resulted in higher activities in comparison to where the inhibitor was not present. This did
not allow a positive value of TrxR activity to be calculated for these samples.
This was disappointing since it might be expected that decreased TrxR activity,
even transiently, in the cell might be due to the chemical modification of the enzyme by
DMF treatment. We chose to examine the effect of DMF in a neuronal cell that was
already available in our laboratory for other studies. Since DMF is used to treat RRMS,
any alterations in TrxR activity (whether transient or prolonged) might assist in
explaining an aspect of the beneficial or side effects of this drug. We would hypothesize
that DMF treatment would reduce enzymatic activity, prompting an increase in oxidative
stress that would result in Nrf2 activation and an increased production of cellular
antioxidant proteins (see Chapter 2 Introduction). Modification of TrxR by DMF may be
a transient and necessary component of inducing a stronger and improved antioxidant

21

balance in the cells. Immunoblotting of the protein lysates from the treated cells
demonstrated that neither levels of TrxR1 nor TrxR2 had changed in the control or
DMF-treated groups (Figure 2.5, TrxR1 and TrxR2 panels). However, due to the inability
to measure TrxR activity in these cells, the protein levels cannot be correlated with
enzymatic activities at this time. Therefore, we look forward to future experiments
involving this cellular model again while utilizing an alternative commercially available
TrxR activity assay to determine the time dependency of DMF-induced decreases in
enzymatic activity. Overall, the preliminary investigations in the studies described
confirmed that fumarate, at least a reactive fumarate ester, could modify the active site of
TrxR.
In contrast, the inability to detect changes in the recombinant TrxR1 activity after
treatment with fumarate may be due to the decreased reactivity of this metabolite versus
DMF. Despite performing repeated experiments with varying incubation times and
temperatures, consistent changes in TrxR activity could not be detected. It may also be
the case that succination of this protein by fumarate is not detectable in this in vitro time
frame. The results of these experiments led me to conclude that I should examine the
effects of elevated fumarate levels on TrxR in cellular models. Cells can provide a more
suitable environment for proteins to be exposed to endogenously produced fumarate for
longer periods of time, and these conditions could provide a better environment to
observe the succination of TrxR.
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Source from <http://www.uniprot.org/uniprot/O89049>

Figure 2.1: Rat Thioredoxin Reductase 1 (TrxR1) protein sequence. Protein sequence
for rat TrxR1 (P089049). Active site Cys (C) and Sec (U) are underlined at C-terminus of
protein. Source: www.uniprot.org
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Figure 2.2: The effects of dimethyl fumarate (DMF) on TrxR activity in vitro. TrxR
activity for rat recombinant TrxR1 protein (1.5 µg) incubated with 0, 5, 50 and 100 µM
DMF for 1 hour at room temperature (n=3). Activity is expressed as the rate of molar
nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mg protein (mean
 S.E.M). Statistically significant differences in enzymatic activity were found in samples
incubated in 50 and 100 µM DMF compared to the control group (*P<0.001).
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Figure 2.3: MS/MS spectrum of DMF-incubated TrxR1 terminal peptide sequence.
The MMF modification was found on one of the active site residues Cys497 or Sec498.
1.5 µg purified rat recombinant TrxR1 samples were incubated in 100 µM DMF for 1
hour at room temperature and resolved by SDS-PAGE before bands were excised and
digested with trypsin before high-resolution mass spectrometry (MS) analysis. The
terminal peptide sequence (SGGDILQSGCUG, detected mass [M+3H]+3=458.50
Daltons) was analyzed using MS/MS where a total of 5 fragments were identified
corresponding to the MMF modification of either Cys497 or Sec498.
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Figure 2.4: The effects of fumarate on TrxR activity in vitro. TrxR activity of rat
recombinant TrxR1 protein (1.5 µg) incubation with 0, 10, 50 and 100 mM fumarate for
6 hours at room temperature (n=3). Activity is expressed as rate of molar nicotinamide
adenine dinucleotide phosphate (NADPH) oxidation per mg protein (mean  S.E.M). No
statistically significant differences in TrxR activity were found between the groups.
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Figure 2.5: TrxR protein levels in N1E-115 cells treated with DMF. N1E-115-1
neuroblastoma cells were treated with dimethyl fumarate (DMF) either 3 hours (lanes 610) or 24 hours (lanes 11-15) prior to protein harvest, and compared to a control group
(lanes 1-5) where no DMF was present. Western blotting was performed on the
cytoplasmic lysates used to analyze protein levels of TrxR1 and TrxR2 in each group.
Levels of -tubulin (DM1A) were used to demonstrate equal protein loading. Molecular
weight markers (kDa) are on the left.
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Table 2.1: Mass Spectrometric data of TrxR1 peptides modified by MMF or DMF. Purified rat recombinant TrxR1 samples were
incubated in 100 µM DMF for 1 hour at room temperature and resolved by SDS-PAGE before bands were excised and digested with
trypsin before high-resolution mass spectrometry (MS) analysis. Initial analysis identified a total of 3 modified Cys residues; Cys177
was modified by MMF, Cys189 modified by MMF and DMF, and Cys modified by MMF. Further MS/MS analysis of the terminal
peptide sequence (SGGDILQSGCUG) revealed the MMF modification on one active site residue, either Cys497 or Sec498.
CPE=pyridyl ethylated cysteine, PSM=peptide spectral matches (indicating the number of times the peptide was detected).
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Peptide Sequence

Swiss Prot #

Monoisotopic Mass
(Da)

YLGIPGDKEYCMMFISSDDLFSLPYCPEPGK

089049;Q5U344

3115.43

C177

5

YLGIPGDKEYCPEISSDDLFSLPYCMMFPGK

089049;Q5U344

3115.43

C189

5

089049;Q5U344

3129.44

C189

5

089049;Q5U344

2745.40
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2

SGGDILQSGCPEUMMFG

-

1373.47

U498

-

SGGDILQSGCMMFUPEG

-

1373.47

C497

-

PE

YLGIPGDKEYC ISSDDLFSLPYC
QQLDSTIGIHPVC

DMF

DMF

PGK

AEIFTTLSVTK

Modification Sites PSMs

CHAPTER 3
THE EFFECTS OF ELEVATED FUMARATE LEVELS ON
THIOREDOXIN REDUCTASE
3.1 Introduction
As described in Chapter 1, thioredoxin reductase (TrxR) contains Cys and Sec
residues in the active site that interchange between a selenenylsulfide and selenolthiol
motif during the catalytic cycles of this enzyme. TrxR is critical for the reduction of the
thioredoxins (Trx) and the modulation of cellular oxidant status; therefore any
compounds that inhibit TrxR are likely to perturb its reductive functions. The
modification of TrxR has previously been demonstrated in vitro by the electrophiles 4hydroxy-2-nonenal (a product of lipid peroxidation) and curcumin (the active component
of the herb tumeric), where the Sec and other Cys residues were irreversibly alkylated
causing diminished enzymatic activity (45, 46). Other TrxR inhibitors include
electrophiles such as gold, platinum or other metal-containing compounds that are
considered highly potent due to their high affinity for sulfur atoms (76, 77). Several
electrophilic compounds containing sulfur, selenium or tellurium have also been
described as either competitive or non-competitive inhibitors of TrxR or its substrates
such as Trx or 5,5’-dithio-bis(2-dinitrobenzoic acid) (DTNB) (77, 78, 79). Recently, the
inhibition of TrxR by other exogenous species such as alantolactone (the active
component of the herb Inula helenium) and sodium arsenite (NaAsO2) has been linked to
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oxidative stress-mediated apoptosis in HeLa cells and pancreatic -cells respectively (80,
81).
Most of the TrxR inhibitors previously identified are exogenous electrophilic
compounds. However, prostaglandins, hormone-like compounds that are involved in
inflammation, and α,β-unsaturated ketones/aldehyde products of lipid peroxidation, such
as 4-hydroxy-2-nonenal, represent the few endogenously produced inhibitors of TrxR
that have been studied to date. In this thesis, I investigated if TrxR was inhibited by the
endogenous metabolite fumarate, during conditions where fumarate levels are elevated.
In particular I was interested in adipocytes matured in high glucose, since we have
previously demonstrated that succination is increased under these conditions (12, 13, 82).
We have also demonstrated that adipocytes in high glucose versus normal glucose
conditions have increased levels of oxidants such as hydrogen peroxide (unpublished
observations). Since protein succination by fumarate is non-enzymatic and irreversible,
this finding might identify a new endogenous inhibitor of TrxR that may in part explain
the susceptibility of some cells to increasing oxidative stress.
3.2 Results
A 3T3-L1 mouse model was used to mimic fumarate-rich diabetic conditions
where adipocytes were matured in either 5 mM or 25 mM glucose medium. Protein was
harvested from the cells after 8 days of maturation, the cytoplasmic fraction was collected
and special caution was taken to ensure that lipid from these cell lysates was removed
following centrifugation. TrxR activity was measured in the cytoplasmic fractions of
adipocyte lysates using the DTNB-reduction assay, as described in Chapter 2. The TrxR
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activity is calculated through the use of a TrxR-specific inhibitor, sodium aurothiomalate
(ATM). The total cellular thiol-reducing activity (samples without inhibitor present) is
measured in parallel with the non-TrxR thiol reducing activity (samples containing TrxR
inhibitor). TrxR activity can be calculated by subtracting the non-TrxR activity (inhibitor
present) from the total thiol-reducing activity (inhibitor not present) and is expressed as
the rate of molar nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per
mg protein (mean  S.E.M). The 5 mM adipocyte group contained 3 out of 5 total
samples that abnormally displayed higher enzymatic activities when the TrxR inhibitor
was present, leaving TrxR activity unable to be calculated for these 3 samples.
Unexpectedly, the average activity measured for the 5 mM adipocytes (n=2) and 25 mM
adipocytes (n=5) were 1.19  0.16 and 3.56  0.41 nmol/min/mg, respectively (Figure
3.1). These results represent statistically different values (*P<0.05), where adipocytes
cultured in high glucose medium (25 mM) display a ~3-fold increase in TrxR activity
compared to adipocytes cultured in normal glucose (5 mM).
Levels of protein succination were analyzed using immunoblotting with an anti2SC antibody and increases in total succinated proteins for 25 mM adipocytes in
comparison to 5 mM adipocytes were confirmed (Figure 3.2, 2SC panel, lanes 6-10 vs.
lanes 1-5). TrxR1 protein levels in these adipocytes were analyzed by immunoblotting to
correlate the measured activities of this enzyme to its abundance in each group, however
no significant differences in band intensities were observed (Figure 3.2, TrxR1 panel).
Levels of α-tubulin (DM1A) were also analyzed using western blotting to demonstrate
equal amounts of protein loading per well (Figure 3.2, DM1A panel).
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In order to produce conditions with enhanced fumarate accumulation, a cell model
was used where 3T3-L1 mouse fibroblasts were transduced with a lentivirus containing
fumarase (Fh) shRNA to induce Fh knockdown (Fh k/d). These were compared to a
control group transduced with a scrambled lentivirus (i.e. fumarase was not knockeddown). In order to ensure that the cells had sufficient incorporation of the virus, the
plasmid also contained a puromycin resistance gene and only puromycin resistant cells
were selected for further propagation. Once these cells were confluent for 7 days they
were harvested and the cytoplasmic protein was collected for analysis. TrxR activity was
measured in the cytoplasmic fractions of cell lysates using the same DTNB-reduction
assay previously described, and the data obtained was expressed as the rate of molar
NADPH oxidation per mg protein (mean  S.E.M). The scrambled group contained 1
sample that exhibited higher activity when the TrxR-inhibitor (ATM) was present,
therefore TrxR activity could not be calculated for this single instance. The average
activity measured for the scrambled samples (n=4) and the Fh k/d samples (n=5) were
1.99  0.89 and 3.05  0.71 nmol/min/mg, respectively (Figure 3.3). The trend for an
increase in activity in the Fh k/d cells was unexpected, however, no statistically
significant differences in TrxR activity were found between the two groups.
In order to confirm that Fh k/d was successful in generating increased succination
in these cells, SDS-PAGE coupled with immunoblotting using a polyclonal anti-2SC
antibody was performed. The immunoblot revealed significant increases in total
succinated proteins for Fh k/d samples in comparison to the scrambled group (Figure 3.4,
2SC panel, lanes 6-10 vs. lanes 1-5). The immunoblot was stripped and additional
blotting was also performed to detect levels of fumarase in both groups, confirming that
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Fh k/d cells had significantly less levels of this protein (Figure 3.4, Fumarase panel).
TrxR1 levels, the cytoplasmic isoform of the enzyme, were also analyzed by western
blotting to detect any differences in the levels of the protein between these groups,
however there were no significant differences in TrxR1 (Figure 3.4, TrxR1 panel).
Finally, the levels of α-tubulin (DM1A) were assessed as a loading control to
demonstrate equal amounts of protein loading per well (Figure 3.4, DM1A panel).
3.3 Discussion
The thioredoxin system, composed of Trx, TrxR and NADPH, is a ubiquitous
disulfide reducing system involved in redox regulation for various cellular processes (39,
40, 83). TrxR is a selenoprotein with high reducing capabilities due to the reactive
penultimate Sec residue in the active site of the enzyme. The two major isoforms of the
TrxR include the cytoplasmic TrxR1 and the mitochondrial TrxR2. The exposed position
and the high reactivity of the Sec residue in TrxR allow the enzyme to be readily
modified by both endogenous and exogenous electrophiles, resulting in decreased
enzymatic activity (45, 46, 77). In Chapter 2 of this thesis I identified a novel TrxR
inhibitor, dimethylfumarate (DMF), which inhibits enzymatic activity due to the
succination of several Cys containing peptides, including the active site (Figure 2.2).
The results of the in vitro experiments with recombinant TrxR1 and DMF served
as a positive control and provided evidence that TrxR could be succinated leading to
reduced enzymatic activity. The next aim of this thesis was to determine if TrxR is
susceptible to succination by elevated levels of fumarate in cellular models. If present,
this modification of TrxR would identify a new endogenous TrxR-inhibiting metabolite
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that is present at elevated levels during certain disease conditions. Hereditary
leiomyomatosis and renal cell cancer (HLRCC) leads to an accumulation of fumarate due
to mutations or deficiencies in the enzyme fumarase, responsible for converting fumarate
to malate (15). In the adipocyte, increased cellular metabolism due to elevated
extracellular glucose concentrations, such as in diabetic conditions, will lead to an
increase in ATP/ADP ratios and an accumulation of ATP. This accumulation inhibits the
mitochondrial electron transport chain through respiratory control, and increasing the
mitochondrial membrane potential (Δψm) and NADH/NAD+ ratio, leading to an
accumulation of fumarate (13) (Figure 1.2). The cell models utilized in the described
studies sought to mimic each of these disease conditions in order to study the effects of
elevated fumarate on TrxR and its activity.
In the adipocyte model, western blotting revealed that increases in levels of total
protein succination in cells grown in high glucose (25 mM) (Figure 3.2, 2SC panel),
however, the levels of TrxR1 were unchanged (Figure 3.2, TrxR1 panel). TrxR activity in
cells matured in 25 mM glucose (n=5) had significantly higher activity compared to those
matured in 5 mM glucose (n=2) (Figure 3.1). It is worth noting that the 5 mM group
contained 3 samples in which TrxR activity could not be measured due to issues with the
activity assay. As mentioned in the results, the assay requires the use of a TrxR-specific
inhibitor (sodium aurothiomalate) that allows TrxR activity to be calculated by
subtracting the non-TrxR thiol-reduction activity from the total thiol-reduction activity.
The 3 samples that were excluded from the reported TrxR activity (Figure 3.1) exhibited
higher activities when the TrxR-inhibitor was present in comparison to the total activity
(no inhibitor present), meaning TrxR activity could not be reliably calculated. In contrast
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to the fibroblast cell model where TrxR1 protein levels and activity were not different
between the two groups, an accurate explanation for the increase in TrxR activity for 25
mM adipocytes is less clear. Keap1 succination by elevated fumarate levels and the
subsequent activation of the Nrf2 pathway could explain an increase in the 25 mM TrxR
activity due to the presence of more of this protein, however protein levels remain the
same as in the 5 mM group (Figure 3.2, TrxR1 panel). While it is unfortunate that we
cannot fully conclude if TrxR is endogenously succinated in adipocytes in vitro, these
results suggest that it may not be. In the future, we hope to further examine the effects of
enhanced fumarate conditions on TrxR in cellular models while utilizing a different TrxR
activity assay.
Despite the large increase in succinated proteins in the Fh k/d fibroblasts, there
was no significant decrease in total TrxR activity when compared to scrambled controls,
in fact the data showed a trend towards increased TrxR activity in the Fh k/d cells (Figure
3.3). This led us to hypothesize that the cells may be compensating for the fumarate
mediated insult by increasing the levels of antioxidant proteins such as TrxR1. However
Western blotting revealed that protein levels of TrxR1 in these fibroblasts did not show
any apparent changes in the fumarase-deficient cells (Figure 3.4, TrxR1 panel). Levels of
the mitochondrial TrxR2 were not analyzed since the lysates used in the activity assays
are cytoplasmic fractions and should contain limited mitochondrial proteins. Considering
the lack of inhibition of enzymatic TrxR activity, as well as the equal levels of TrxR1
protein between the scrambled and Fh k/d cells, it is appears that TrxR was not modified
by fumarate as originally predicted. Fumarate is not as reactive as DMF, and perhaps it is
unable to compete with the endogenous TrxR substrates, such as Trx, and induce
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succination. It is also possible that elevated fumarate levels in Fh k/d fibroblasts lead to
the succination of TrxR1 and the protein was rapidly turned-over. Elevated levels of
fumarate are also known to cause succination of Kelch-like ECH-associated protein-1
(Keap1) that, under normal circumstances, interacts with the transcription factor nuclear
factor (erythroid-derived 2)-like-2 (Nrf2), preventing its translocation to the nucleus and
promoting transcription of target genes (2, 7, 82). Succinated Keap-1 results in its
dissociation with Nrf2, allowing Nrf2 to promote the transcription of various
cytoprotective and antioxidant enzymes, including TrxR1 (84, 85, 86). Degradation of
succinated TrxR1 and the expression of additional protein in Fh k/d cells after Nrf2
activation could explain the relatively equal amount of TrxR activity and TrxR1 protein
levels compared to the control samples. The assessment of TrxR activity over several
hours, or in the presence of cycloheximide to prevent translation of new protein, may be
required to determine if a relatively equal rate of synthesis:degradation contributed to the
results observed.
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Figure 3.1: TrxR activity in 5 mM vs 25 mM 3T3-L1 adipocytes. 3T3-L1 adipocytes
were matured in 5 mM or 25 mM glucose for 8 days. Cellular thioredoxin reductase
(TrxR) activity was measured in lysates using a DTNB reduction assay and expressed as
the molar rate of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per
mg protein (5 mM glucose n=2, mean ± S.E.M.; 25 mM glucose n=5, mean ± S.E.M.).
Significant differences were found between 5 mM and 25 mM groups (*P < 0.05) with
the 25 mM group showing a ~3 fold increase in TrxR activity.
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Figure 3.2: Western blot of TrxR levels in 5 mM vs 25 mM 3T3-L1 adipocytes. 3T3L1 adipocytes were matured in 5 mM (lanes 1-5) or 25 mM (lanes 6-10) glucose for 8
days. Protein (30 µg) was separated using 1-D SDS-PAGE and detection of 2SC was
performed using a polyclonal anti-2SC antibody. Western blotting was also used to
analyze protein levels of TrxR1 to determine if differences existed between the two
groups. The levels of -tubulin (DM1A) were determined to sure equal protein loading.
MW markers are shown in kDa on the left.
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Figure 3.3: TrxR activity in Scrambled vs. Fh k/d 3T3-L1 fibroblasts. 3T3-L1
fibroblasts were transfected with a scrambled lentivirus or a lentivirus containing an
shRNA that knocks down fumarase (Fh). Cellular thioredoxin reductase (TrxR) activity
was measured in lysates using a DTNB reduction assay and expressed as the molar rate
of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mg protein
(scrambled n=4, mean ± S.E.M.; Fh k/d n=5, mean ± S.E.M.). No significant differences
between scrambled and Fh k/d groups.
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Figure 3.4: Western blot of TrxR levels in scrambled vs Fh k/d 3T3-L1 fibroblasts.
3T3-L1 fibroblasts were transfected with a scrambled virus (lanes 1-5) or viral shRNA
that knocks down fumarase (Fh) (lanes 6-10). Protein (30 µg) was separated using 1-D
SDS-PAGE and detection of 2SC was performed using a polyclonal anti-2SC antibody.
Western blotting was also used to analyze protein levels of TrxR1 to determine if
differences existed between the two groups, and to analyze levels of fumarase to confirm
the knockdown in Fh k/d cells. MW markers are shown in kDa on the left and -tubulin
(DM1A) was used as a loading control.
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CHAPTER 4
THE EFFECTS OF FUMARATE AND DIMETHYL FUMARATE (DMF)
ON GLUTATHIONE PEROXIDASE
4.1 Introduction
Glutathione peroxidase (GPx) is a highly conserved selenoenzyme that
contributes significant protective functions as a scavenger of damaging reactive oxygen
species (ROS) in the cell. Due to its essential role, identifying compounds that may
impede its normal function would prove to be very beneficial in understanding how ROS
imbalance occurs during disease states. In contrast to thioredoxin reductase (TrxR), there
are fewer inhibitors of GPx described in the literature, and the detailed mechanisms of
inhibition for most of those identified are not completely understood. Recently,
proteomic analysis has identified the succination of Cys202 of GPx1 in a fumarase (Fh)
deficient tumor, where levels of fumarate are enhanced due to a mutation of the Kreb’s
cycle enzyme responsible for converting fumarate to malate (16). Although the effects of
this modification on GPx activity were not investigated, this result established that this
enzyme could be modified by fumarate intracellularly. Although Cys202 is not in the
active site of GPx, its ability to be succinated, and the presence of an additional Sec in
this enzyme’s active site, provided a reason for this thesis to examine GPx activity in
similar models where fumarate is enhanced.
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Coenzyme A, an acyl carrier involved in the synthesis and oxidation of fatty acids
and the oxidation of pyruvate, has also been described as a GPx inhibitor at low
concentrations, however its mechanism of interaction with GPx is largely unknown (87).
4-hydroxy-nonenal (HNE), an aldehyde produced during lipid peroxidation and a
previously described TrxR inhibitor (46), has been demonstrated to cause concentrationdependant inhibition of bovine erythrocyte GPx, which was hypothesized to be the
caused by the modification of non-specific Cys residues (88). The exact mechanism was
not identified, however in experiments where GPx was pre-incubated with thiols such as
glutathione (GSH), the inhibition by HNE was not observed; proposed to be blocked by
GSH binding to GPx (88).
More specifically, the oxidation and subsequent inactivation of GPx has been
described in greater detail using both endogenous and exogenous pro-oxidants. S-nitrosoN-acetyl-D,L-penicillamine (SNAP) is an exogenous precursor to the vasodilator nitric
oxide (NO) and causes the oxidation of Sec and Cys residues on GPx, resulting in the
formation of either disulfide (Cys-Cys) or selenyl sulfide (Sec-Cys) bonds that cause
inhibition of the enzyme, presumably inhibiting the catalytic cycle (89). More potent
oxidants such as peroxynitrite, a strong nucelophilic product of nitric oxide (NO) reacting
with superoxide (O2-), and 3-morpholinosydnonimine-N-ethylcarbamide, a precursor to
the oxidant, peroxynitrite, also caused dose-dependent inhibition of GPx through
oxidative modification of thiols or selenols (89, 90). Currently, oxidative modification
represents the most characterized type of GPx inhibition; however this thesis aims to
determine if irreversible succination by endogenously produced fumarate is also capable
of inhibiting GPx in cell culture systems.

42

4.2 Results
In order to test the ability to modify GPx and alter its activity in vitro,
experiments were conducted using bovine erythrocyte glutathione peroxidase (GPx,
predominantly GPx1). The protein was incubated in 0, 10, 25, 50 and 100 µM
dimethylfumarate (DMF, a reactive fumarate ester that we considered a positive control)
for 1 hour at room temperature. GPx activity was measured and expressed as the molar
rate of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mL (mean
 S.E.M., Figure 4.1). Statistically significant differences in GPx activity could not be
detected, even with elevated concentrations of DMF. A similar experiment was
performed where bovine erythrocyte GPx was incubated in 0, 5, 10, 15, 25 and 50 mM
fumarate for 6 hours at room temperature. GPx activity was measured and expressed as
the molar rate of NADPH oxidation per mL (mean  S.E.M., Figure 4.2). However no
statistically significant differences in GPx activity could be detected. Several additional
experiments were performed where the protein was treated with either DMF or fumarate
for varying incubation times and temperatures, however no consistent reduction in
activity was detected (data not shown).
In order to mimic diabetic conditions, a cell model was used where 3T3-L1 mouse
adipocytes were matured in either 5 mM or 25 mM glucose medium. GPx activity was
measured in the cytoplasmic fractions of cell lysates and expressed as the rate of molar
NADPH oxidation per mg protein (mean  S.E.M). The average activity measured for the
5 mM adipocytes (n=5) and 25 mM adipocytes (n=5) were 10.60  0.64 and 7.91  0.73
nmol/min/mg, respectively (Figure 4.3). These results represent statistically different
values (*P<0.05), where adipocytes cultured in high glucose medium (25 mM) display an
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average ~25% decrease in GPx activity compared to adipocytes cultured in normal
glucose (5 mM). These results suggested that GPx activity was reduced in high glucose
specifically, potentially as a result of succination.
SDS-PAGE followed by immunoblotting was performed to analyze the
differences in total succinated proteins in adipocytes matured in 5 mM vs 25 mM glucose
(Figure 4.4, 2SC panel, lanes 1-5 vs. lanes 6-10). Western blotting was also performed to
analyze protein levels of the two most abundant GPx isoforms, GPx1 and GPx4, and to
correlate these levels to enzymatic activity data. There were no obvious differences in
protein levels of either GPx1 (Figure 4.4, GPx1 panel) or GPx4 (Figure 4.4, GPx4 panel)
for adipocytes matured in 5 mM vs. 25 mM glucose. Protein levels of α-tubulin (DM1A)
were also analyzed using western blotting and used as a loading control (Figure 4.4,
DM1A panel). Densitometry was performed on the immunoblots to determine the relative
ratio of intensity of GPx1 (Figure 4.5) and GPx4 (Figure 4.6) bands normalized to DM1A
band intensity for 5 mM or 25 mM sample, confirming that no significant differences in
either of these proteins between the groups could be established.
An additional cell culture model was used to examine the effects of enhanced
fumarate accumulation on intracellular GPx; the same fibroblast model was used as for
the TrxR experiments (see Chapter 3). 3T3-L1 mouse fibroblasts were transduced with
fumarase knock-down (Fh k/d) lentiviral shRNA and compared to a control group
containing a scrambled lentivirus (i.e. fumarase was not knocked-down). The virus also
contained a puromycin resistance gene in the plasmid to ensure the selection of only the
cells transduced with the virus. After 7 days of confluency, cellular protein was harvested
and the cytoplasmic fractions were collected for analysis. GPx activity was measured in
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the cytoplasmic fractions of cell lysates and expressed as the rate of molar NADPH
oxidation per mg protein (mean  S.E.M). The average activity measured for the
scrambled samples (n=5) and the Fh k/d samples (n=5) were 34.25  1.76 and 39.45 
2.31 nmol/min/mg, respectively (Figure 4.7). However no statistically significant
differences in GPx activity were detected between the two groups.
Increases in total protein succination were detected through immunoblotting in Fh
k/d samples in comparison to scrambled controls (Figure 4.8, 2SC panel, lanes 6-10 vs.
lanes 1-5). Decreased levels of fumarase were also detected in the Fh k/d group
compared to the scrambled control by immunoblotting, confirming its knockdown by
shRNA (Figure 4.8, Fumarase panel). Western blots were also probed for GPx1 to detect
any changes in protein levels between these groups, however there were no apparent
differences (Figure 4.8, GPx1 panel). Levels of α-tubulin (DM1A) were used as a loading
control to demonstrate equal amounts of protein loading per well (Figure 4.8, DM1A
panel).
4.3 Discussion
My original hypothesis predicted that incubations with the highly reactive DMF
or the endogenous metabolite fumarate would result in decreased enzymatic activity.
However, contrary to this hypothesis, consistent changes in recombinant bovine GPx
activities could not be observed after incubation with either DMF or fumarate in vitro,
despite performing several experiments in each of these models. The position of the
active site Sec and its accessibility to molecules such as fumarate or DMF may be related
to observed lack of modification. Molecular modeling of GPx reveals that the active site
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is located at the ends of long -helices and is surrounded by aromatic side-chains (91,
92). Sec resides in position 47 of the 201 amino acids in the bovine GPx sequence
(Figure 4.9), and may not be as substrate-accessible if there are some negatively charged
amino acids nearby since fumarate contains 2 carboxyl groups. Treatment of HeLa cells
with the cytotoxic compounds iludin S, a natural compound produced by fungi, and
acylfulvene (AF), a semi-synthetic derivative of iludin S, caused inhibition of TrxR by
irreversible binding to Sec but had no effect on GPx activity (92). While GPx may not be
as reactive, this study highlights the increased exposure of the TrxR active site and
therefore its increased susceptibility to chemical modification in comparison to the GPx
active site. However, while I intend to pursue TrxR further, my cumulative data thus far
suggests that fumarate may not be sufficiently reactive with either protein active site in
vitro.
Increases in total protein succination by immunoblotting were detected in Fh k/d
fibroblasts compared to scrambled controls (Figure 4.8, 2SC panel), however no
detectable decrease in GPx activity could be observed (Figure 4.7), despite the initial
hypothesis of this enhanced endogenous fumarate model leading to the succination and
inhibition of this selenoenzyme. The protein levels of GPx1 did not appear to change
after western blotting analysis in the Fh k/d cells (Figure 4.8, GPx1 panel), consistent
with the activity data. Although fumarate levels were elevated in Fh k/d cells, it is
unlikely that succination occurred on the Sec residue of GPx, which would result in a
decrease in enzymatic activity. In contrast, a ~25% decrease in GPx activity was detected
in 3T3-L1 adipocytes matured in high glucose (25 mM) versus cells matured in normal
glucose (5 mM) (Figure 4.5). In order to correlate GPx activity to the levels of this
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protein, both the GPx1 and GPx4 isoforms were analyzed with western blotting. The
enzymatic activity assay measures total GPx activity, where each of the isoforms
contributes to the activity detected. Therefore, we were interested in determining GPx4
levels for the adipocyte model because this enzyme is responsible for protection from
lipid peroxidation and we hypothesized that GPx4 is more abundant in the lipid-rich
adipocyte. Western blotting and densitometric analysis revealed no significant changes in
the protein levels of GPx1 or GPx4 (Figure 4.4, GPx1/GPx4 panel), suggesting that the
decrease in enzymatic activity detected in 25 mM cells is attributed to the chemical
modification and inhibition of GPx as opposed to decreased amounts of this enzyme.
Although a pronounced decrease in GPx activity was detected in an adipocyte
model that mimics hyperglycemic conditions, and it appears it is not due to protein
succination, the reason for decreased activity can only be speculated upon without further
investigation. Adipocytes contain high levels of triglycerides that are subject to lipid
peroxidation, a process that produces reactive aldehydes (e.g. HNE) that have been
shown to covalently modify proteins (a process known as carbonylation) (93). Adipocyte
proteins are among the most heavily carbonylated (93), and it is possible that this type of
modification could be contributing to the observed decrease in GPx activity for
adipocytes matured in high glucose. Unfortunately I was unable to successfully
immunoprecipitate GPx from these samples with the antibodies available in our
laboratory, however future work on this project may lead to the successful isolation of
this protein for proteomic analysis and detection of possible carbonylation or succination.
Regardless, we know that hyperglycemic conditions will lead to in an increase in
intracellular fumarate levels as well as glucose-derived H2O2, creating a greater need for
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antioxidants such as GPx (13, 38). Our cell model displayed a significant reduction of
GPx activity in cells cultured in 25 mM glucose, and I believe these results confirm that
the adipocyte GPx capability is defective during glucotoxic conditions.
Since the assay for GPx activity provided reliable data and we did not detect
decreases in the Fh k/d cells (Figure 4.7), it appears that fumarate alone does not modify
the activity of GPx. As mentioned earlier in this Discussion, it is possible that other
factors such as negative charges surrounding the Sec in the folded protein decrease
fumarate reactivity with GPx, despite the pKa of the active site Sec. Further studies on the
succination of other proteins containing low pKa thiols versus accessible thiols may allow
us to further understand the factors that govern a proteins reactivity with fumarate.
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Figure 4.1: The effects of DMF on GPx activity in vitro. Enzymatic activity of bovine
erythrocyte glutathione peroxidase (GPx) incubated with 0, 10, 25, 50 or 100 µM
dimethyl fumarate (DMF) for 1 hour at room temperature (n=3). Activity is expressed as
mean  S.E.M. of the molar rate of NADPH oxidation per mL of protein. No statistically
significant differences were found in GPx activity between the groups.
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Figure 4.2: The effects of fumarate on GPx activity in vitro. Enzymatic activity of
bovine erythrocyte GPx incubated with 0, 10, 15, 25 or 50 mM fumarate for 6 hours at
room temperature. Activity is expressed as mean  S.E.M. of the molar rate of NADPH
oxidation per mL of protein (n=3). No statistically significant differences were found in
GPx activity between the groups.
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Figure 4.3: GPx activity in 5 mM vs 25 mM 3T3-L1 adipocytes. 3T3-L1 adipocytes
were matured in 5 mM or 25 mM glucose for 8 days. Cellular TrxR activity was
measured in lysates using colorimetric GPx activity assay that utilizes glutathione (GSH),
glutathione reductase (GR) and nicotinamide adenine dinucleotide phosphate (NADPH).
GPx activity is expressed as the molar rate of NADPH oxidation per mL of protein (5
mM glucose n=5, mean ± S.E.M.; 25 mM glucose n=5, mean ± S.E.M.). Significant
differences were found between 5 mM and 25 mM groups (*P < 0.05) with the 25 mM
group showing a ~25% decrease in GPx activity.

51

Figure 4.4: Western blot of GPx levels in 5 mM vs. 25 mM 3T3-L1 adipocytes. 3T3L1 adipocytes were matured in 5 mM (lanes 1-5) or 25 mM (lanes 6-10) glucose for 8
days. Protein (30 µg) was separated using 1-D SDS-PAGE and detection of 2SC was
performed using a polyclonal anti-2SC antibody. Western blotting was also used to
analyze protein expression of GPx1 and GPx4 to determine if differences existed between
the two groups using levels of -tubulin (DM1A) as a loading control. MW markers are
shown in kDa on the left.
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Figure 4.5: Densitometric analysis of GPx1/DM1A levels in 3T3-L1 adipocytes.
Densitometric analysis of GPx1/DM1A levels from western blot of 3T3-L1 adipocytes
grown in 5 mM (n=5) or 25 mM (n=5) glucose, expressed as mean ±S.E.M. No statistical
significances were detected.
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Figure 4.6: Densitometric analysis of GPx4/DM1A levels in 3T3-L1 adipocytes.
Densitometric analysis of GPx4/DM1A levels from western blot of 3T3-L1 adipocytes
grown in 5 mM or 25 mM glucose, expressed as mean ±S.E.M. No statistical
significances were detected.
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Figure 4.7: GPx activity in scrambled vs. Fh k/d 3T3-L1 fibroblasts. 3T3-L1
fibroblasts were transduced with a scrambled virus or viral shRNA that knocks-down
fumarase (Fh). Cellular GPx activity was measured in lysates using a colorimetric GPx
activity assay that utilizes glutathione (GSH), glutathione reductase (GR) and
nicotinamide adenine dinucleotide phosphate (NADPH). GPx activity is expressed as the
molar rate of NADPH oxidation per mL of protein (scrambled n=5, mean ± S.E.M.; Fh
k/d n=5, mean ± S.E.M.). No significant differences were detected between scrambled
and Fh k/d groups.
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Figure 4.8: Western blot of GPx levels in scrambled vs. Fh k/d 3T3-L1 fibroblasts.
3T3-L1 fibroblasts were transduced with a scrambled virus or viral shRNA that knocksdown fumarase (Fh). Protein (30 µg) was separated using 1-D SDS-PAGE and detection
of 2SC was performed using a polyclonal anti-2SC antibody. Western blotting was also
used to analyze protein expression of GPx1 to determine if differences existed between
the two groups, and to analyze levels of fumarase to confirm the knock-down in Fh k/d
cells. MW markers are shown in kDa on the left and -tubulin (DM1A) was used as a
loading control.
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Figure 4.9: Bovine erythrocyte GPx protein sequence. Protein sequence from bovine
erythrocyte GPx (P00435). Sec is underlined at position 52.
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CHAPTER 5
FUTURE DIRECTIONS
Our laboratory is interested in continuing to study the effects of fumarate and
fumarate esters on selenocysteines. The results of this thesis indicate that thioredoxin
reductase (TrxR) and its active site Sec may be more readily succinated by dimethyl
fumarate than glutathione peroxidase (GPx), however, neither protein Sec residue
appeared to react with endogenously produced fumarate as readily as we initially
predicted. To further understand this we will continue a new collaboration with Dr.
Gianluca Miglio (University of Turin, Italy) modeling how charges and substrate
accessibility determine the likelihood of succination, based on available crystal structures
of Sec-containing proteins. Although the in vitro experiments from this thesis identified
dimethyl fumarate (DMF) as a new inhibitor of TrxR through proteomic analysis, we
hope to continue these experiments to confirm that the selenocysteine (Sec) residue is in
fact the target of succination by the drug and the reason for the observed decrease in
enzymatic activity.
An immediate goal, following the completion of this thesis, is to continue with
experiments to investigate the rapid reactivity of the DMF with cellular targets, as this
drug is likely acting on a plethora of intracellular proteins. New efforts in our laboratory
are underway to identify these targets and define the downstream effects of DMF.
Ultimately it is hoped that these studies will help us better understand both the beneficial
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actions, as well as the side effects of this drug, and facilitate the design of more targeted
therapeutic strategies for the treatment of multiple sclerosis (MS). In our further
investigation of the effects of DMF on TrxR, we plan to use an alternative commercially
available activity assay (based on the reduction of insulin disulfides by reduced
thioredoxin with thioredoxin reductase and NADPH) that will hopefully provide more
reliable data for cellular TrxR activity in our N1E-115 model. Our goal is to determine
the effects of DMF after 1 hour and 3 hours of treatment, while utilizing cycloheximide
in various groups to inhibit protein synthesis. This will prevent the cells from
synthesizing additional antioxidants such as TrxR1 in response to the insults from DMF,
and we hypothesize that TrxR activity might be reduced. While we accept that GPx may
not be succinated and inhibited by fumarate, the accessibility of the TrxR active site
encourages us to pursue these planned studies with it to ensure that we have properly
determined whether it can be modified by endogenously produced fumarate.
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CHAPTER 6
METHODS AND MATERIALS
Materials
All chemicals were purchased from Sigma Aldrich (St. Louis, MO), unless
otherwise noted. Preparation of anti-2SC antibody was performed as described (Nagai
2007) by Eurogentec (Fremont, CA). Polyvinylidene fluoride (PVDF) was purchased
from GE Healthcare (Fairfield, CT). Tris Base, L-glycine, and sodium dodecyl sulfate
(SDS) were purchased from Fisher Scientific (Waltham, MA). Tween-20 and
CriterionTGX Precast Gels were from Bio-Rad (Hercules, CA). Thioredoxin
Reductase 1 (TrxR1) rat recombinant protein was purchased from IMCO (Stockholm,
Sweden) and Glutathione Peroxidase Colorimetric Activity assay were purchased from
Cayman Chemicals (Ann Arbor, MI).
Protein Extraction from Cells
All samples and reagents were kept on ice while protein was harvested. The cells
were washed three times with phosphate buffered saline (PBS). The cells were collected
in 50 mM Tris-HCl-EDTA assay buffer and homogenized on ice using a plastic
homogenizer. The samples were then centrifuged at 10,000 g for 15 minutes at 4C and
the supernatant was collected. Activity assays were performed on cell lysate supernatants
before being frozen at -70C for future experiments.
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Measurement of Thioredoxin Reductase 1 (TrxR1) Activity in Recombinant
Samples after Treatment with Fumarate or Dimethyl Fumarate (DMF)
TrxR activity was measured in a clear 96-well (Corning) plate format using an
adaptation of the method previously published (Holmgren et al., 2014). 1.5 g of rat
recombinant TrxR1 protein (Cayman Chemicals, Ann Arbor, MI) was added to each
sample/enzymatic in 50 mM Tris-HCl-EDTA assay buffer. Each sample was pre-reduced
with 30-35 g of nicotinamide adenine dinucleotide phosphate (NADPH) for 5 minutes
prior to addition of either fumarate (0-100 mM) or DMF (0-100 M). The samples were
left to incubate for varying time periods (1-18 hours) at either room temperature or 4C.
After incubation an additional 30-35 g of NADPH was added to each enzymatic well,
quickly followed by the addition of 5 mM 5,5’-dithio-bis(2-dinitrobenzoic acid) (DTNB)
to initiate the reactions. Background/Non-enzymatic wells contained only Tris-HClEDTA assay buffer with DTNB and were subtracted from the absorbance values obtained
for the wells containing protein. Final volumes in each well totaled 200 L. Absorbances
were measured at the 405 nm wavelength using a Tecan Safire2 plate reader every minute
for 5 minutes. Data was collected using XFluor4 software (a Microsoft Excel macro).
Measurement of Thioredoxin Reductase (TrxR) Activity in Cell Extracts
TrxR activity was measured in a clear 96-well (Corning) plate format using an
adaptation of the method published by (45). Sample wells contained 100-400 g of
protein from cell lysates, 60-70 g of NADPH, and 50 mM Tris-HCl-EDTA assay buffer,
to a final volume of 200 l. Replicate samples containing 20 M of the TrxR inhibitor
sodium aurothiomalate (ATM) were also prepared in some cases. Positive control wells
61

contained 1.5 g of rat recombinant TrxR1, 60-70 g NADPH, and 50 mM Tris-HClEDTA assay buffer. The enzymatic reactions were initiated by the addition of 5,5’-dithiobis(2-dinitrobenzoic acid) DTNB to each well, after which the absorbance for each well
was immediately measured at 405 nm every minute for 5 minutes using a Tecan Safire2
plate reader. Background/Non-enzymatic wells contained only Tris-HCl-EDTA assay
buffer with DTNB and were subtracted from the absorbance values obtained for the wells
containing protein. Data was collected using XFluor4 software (a Microsoft Excel
macro).
Measurement of Glutathione Peroxidase (GPx) Activity in Cell Lysates
GPx activity was measured in a clear 96-well (Corning) plate using a Glutathione
Peroxidase colorimetric activity assay kit (Cayman Chemicals, Ann Arbor, MI),
according to the manufacturer’s instructions. Sample wells contained 15-18 g of protein
from cell lysates, 50 L co-substrate mixture (containing NADPH, glutathione, and
glutathione reductase), and 50 mM Tris-HCl-EDTA assay buffer. Positive control wells
contained 20 L of kit-supplied Bovine-erythrocyte GPx protein, 50 L co-substrate
mixture, and 100 L Tris-HCl-EDTA assay buffer. Background/non-enzymatic wells
contained 50 L co-substrate mixture and 120 L Tris-HCl-EDTA assay buffer. The
enzymatic reactions were initiated by the addition of 20 L of cumene hydroperoxide,
after which the absorbance for each well was measured at 340 nm (monitoring the loss of
NADPH) each minute for 5 minutes using a Tecan Safire2 plate reader. Data was
collected using XFluor4 software (a Microsoft Excel macro).
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Western Immunoblotting
Samples were prepared using 30 g for cell lysates with the addition of 5-7 L
4X Laemmli loading buffer. The samples were then boiled at 95C for 15 minutes, flash
centrifuged then loaded onto 7.5%, 12%, or 18% agarose gels and electrophoresed at 200
V for 50-70 minutes. The protein was transferred to a PVDF membrane in transfer buffer
at 250 mA for 100 minutes or 40 mA at 4C. The membrane was Ponceau stained then
washed 3 times for 5 minutes in 20 mM Tris-Glycine containing % Tween20 wash
buffer, and blocked in 5% non-fat milk or 5% bovine serum albumin (BSA) if suggested
by antibody manufacturer. Membranes were probed using primary rabbit polyclonal anti2SC (1/8000). Antibodies against fumarase (Lot #1), TrxR2 (Lot #1) and DM1A tubulin
(Lot #8) were from Cell Signaling Technology (Danvers, MA), GPx1 (Lot #GR82550-9)
from Novus Biologicals (Littleton, CO), GPx4 (Lot #GR251529-3) from Abcam
(Cambridge, MA), TrxR1 (Lot #CBZG021007) from R&D Systems (Minneapolis, MN).
HRP-coupled secondary antibodies were used where appropriate; anti-mouse (Lot
#X0328) from Vector Labs (Burlingame, CA) and anti-rabbit (Lot #26) from Cell
signaling Technology (Danvers, MA). Pierce ECL 2 Western Blotting Substrate was
used prior to the detection of chemiluminescence using photographic film (Denville
Scientific, Metuchen, NJ). ImageJ software (NIH) was used to quantify band intensity by
densitometry.
In-Gel Protein Digestion
Recombinant rat thioredoxin reductase 1 (TrxR1) was incubated in the absence or
presence of 100 M DMF for 20 hours at 37C. Following incubation, 3 g of protein
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was electrophoresed by SDS-PAGE as described (section above). Following
electrophoresis the gel was stained with Coomassie Brilliant Blue for 1 hour, followed by
de-staining in 7% acetic acid/10% methanol for 24 hours to detect TrxR protein. The
excised gel bands cut into several smaller pieces before being washed in a 50/50%
methanol/acetic acid solution for several days to completely remove Coomassie stain. Gel
bands were then washed in 50mM ammonium bicarbonate in 50% acetonitrile, then
100% acetonitrile for 5 mins and allowed to dry using a SpeedVac centrifuge. Sample
was reduced with 10 mM dithiothreitol (DTT) was and then alkylated using 170 mM 4vinylpyridine (4-VP). Trypsin digestion was carried out overnight at 37C in the presence
of 1.5 ng sequence grade modified trypsin (Promega, Madison, WI) in 50 mM
ammonium bicarbonate. The supernatant and extracts with 5% formic acid in 50%
acetonitrile, then 100% acetonitrile and were pooled and dried down in a SpeedVac
centrifuge to ~20 µL. The digested samples were analyzed on a Dionex Ultimate 3000LC system (Thermo Scientific, Rockford, IL) coupled to a Velos Pro Orbitrap mass
spectrometer (Thermo Scientific, Rockford, IL).
Data Analysis
All graphs were generated in Sigmaplot 11. Statistical analyses of the data were
performed on SigmaStat software (Sigmaplot 11, San Jose, CA). All data were plotted as
means ± S.E.M. An unpaired Student t test was used to test for statistical differences
between two sets of data. A One Way ANOVA using Holm-Sidak test was used when
comparing 3 or more sets of data. Differences were considered statistically significant at
*

p<0.05.
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APPENDIX A
BUFFER PREPARATIONS
Assay Buffer
The buffer was prepared in 250 mL stocks containing 50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA. The buffer was stored at 4oC.

Running Buffer
One liter of 10x stock was prepared containing 250 mM Tris-HCl, 1920 mM glycine and
10% (SDS).

Transfer Buffer
One liter of 10X stock was prepared containing 250 mM Tris-HCl, 1920 mM glycine.
Methanol was added at 20% for transfer process.

Wash Buffer
One liter of 10X stock was prepared containing 200 mM Tris-HCl, pH 7.4. Tween-20
was added at 0.05% to 1X was buffer.
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APPENDIX B
LOWRY ASSAY
Pipette the specific amounts of reagents into the microplate in the order listed. All
samples are prepared in duplicates.

Table B.1: Preparation of BSA standard curve for the Lowry assay.

Probe

BSA
(µL)

H20
(µL)

Copper Incubation FolinIncubation
Reagent
Ciocolateu
(µL)
(µL)

Blank

0

20

20

1

1

19

20

2

2

18

20

60

3

3

17

20

60

4

4

16

20

60

5

8

12

20

60

6

10

10

20

60

7

20

0

20

60

15

20

60

Sample 5

20
minutes
at 37oC

60
60

30
minutes
at 37oC

Stock BSA
Dissolve 50 mg BSA (Bovine Serum Albumin) in 10 mL deionized water=5 mg/mL
stock/working solution
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Working Solutions: Dilute 400 µL of 5 mg/mL stock in 600 µL water=2 mg/mL solution

Table B.2: Preparation of copper reagent for Lowry assay.
Stock Solution

Working Solution

Copper Sulfate 1% (w:v)

100 µL

Sodium Tartrate 2% (w:v)

100 µL

Sodium Carbonate 10% (w:v) in 0.5 M NaOH

2 mL

Folin-Ciocolateu Phenol Reagent: Purchased as a 2 N stock solution. For working
solution at 500 µL of stock solution to 5.5 mL of water
Read absorbance at 660nm.
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APPENDIX C
WESTERN BLOTTING
Gel Electrophoresis

1. After determining the protein content from the Lowry assay, 30-40 µg of protein was
dissolved in water and 5 µL of Laemmli loading buffer was added.

2. Boil the samples for 15 min at 95°C then flash centrifuge.

3. Remove tape and comb from Bio-Rad pre cast Criterion gel and place in cassette.

4. Fill the cassette tank and gel with Tris/Glycine/SDS running buffer.

5. Load the samples into their individual lanes and 8 µL of marker into your lane of
choice.

6. Run the gel at 200 V for 60 min.

Wet Transfer

1. Remove the gel from the pre-cast and cut to size
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2. Soak the gel in Tris/Glycine/Methanol transfer buffer for 15 min.

3. Charge the PVDF membrane for ~30 sec in methanol. Soak the 2 pieces of blotting
paper, 2 sponges, and the membrane in Tris/Glycine/methanol for 15 min.

4. Assemble the transfer apparatus, starting with the black side first. Keep all materials
soaking in transfer buffer during the assembly.

5. Place the sponge flat on the black side, followed by a piece of blotting paper. Next,
place the gel on top followed by the PVDF membrane. Roll out any air bubbles between
the gel and membrane using a roller. Finally, put the remaining piece of blotting paper on
top of the membrane and the sponge on top.

6. Assemble the apparatus and transfer at 250 mA for 100 min or 40 mA for at least 12
hrs.

7. Remove the membrane from the apparatus and wash 3 times with nanopure water. 8.
Place the membrane in ponceau stain for 5 min then wash with nanopure water to
visualize the bands. Inspect the membrane for equal loading and where bubbles formed
during the transfer process. Wash the ponceau stain off the membrane with Tris-HCl
wash buffer.

9. Block the membrane in 5% non-fat dry milk or 5% BSA for at least 1hr.

Immunostaining for 2SC

1. Prepare 1% milk by diluting the 5% milk 1:4 in Tris-HCl wash buffer.
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2. Add 2SC antibody to the milk in a 1:5000 dilution. Incubate for at least 1 hr on the
rocker.

3. Pour off the antibody and wash the membrane 3 times in wash buffer for 5 min each.

4. Add secondary antibody anti-rabbit to 1% milk, 1:15000 dilution and incubate for 1hr
at room temperature.

5. Pour off the milk and was the membrane 3 times for 5 min each in wash buffer.

Developing

1. Prepare ECL solution by adding solution B to solution A and in a 1:40 dilution.

2. Add the ECL to the membrane and incubate for 5 min. Place the membrane in the
cassette and cover with plastic wrap.

3. In the dark room, place a piece of X-ray film over the membrane then develop. Inspect
the film after it has developed and adjust the exposure times accordingly.

Buffers

1. Stock Running Buffer: 10X SDS – 30.3 g Tris base, 144 g glycine and 10 g SDS
dissolved to 1 L water
- Working solution=100mL of 10X stock diluted to 1L water
2. Stock Transfer Buffer: 10X transfer – 30.3 g Tris base and 144 g glycine dissolved to
1 L water
- Working solution=150 mL of 10X stock and 300 mL of methanol diluted to 1 L
water
3. Stock Wash Buffer: 10X Wash – 24.4 g Tris base dissolved to 1 L water, pH 7.4
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-

Working solution=100 mL of 10X stock and 500 µL Tween-20 diluted to 1 L
water
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APPENDIX D
CELL CULTURE
3T3-L1 Cell Culture:
3T3-L1 murine fibroblasts were purchased from American Type Culture
Collection (Manassas, VA) and maintained in DMEM containing 5 mM glucose, 10%
Bovine Calf Serum (Thermo Scientific), 1% penicillin/streptomycin (CellGro) at 37C
with 5% CO2 and 95% humidity. Growth medium was replaced every 2 days. At 70-80%
confluence the cells were removed with trypsin (Thermo Scientific), neutralized with
excess growth medium, and collected by centrifugation at 1000 g for 5 min. The cells
were then re-suspended in growth medium for a new passage. 3T3-L1 fibroblasts were
seeded at a density of 100,000 cells per 10 cm2 petri dish. 3T3-L1 fibroblasts were
induced to differentiate when the fibroblasts reached 24 hours post-confluence (~3-4
days) in DMEM with 10% Fetal Bovine Serum (Atlanta Biologicals), 1%
penicillin/streptomycin, insulin (10 μg/mL), dexamethasone (0.3 μM), 3-isobutyl-1methylxanthine (0.5 mM) and 30 mM glucose for 3 days. At day 0, differentiation
medium was removed, cells were washed with PBS and maturation medium containing 5
mM/0.3 nM or 30 mM/3 nM glucose/insulin was applied. The medium was changed
every 2 days and the adipocytes were matured in 5 mM or 30 mM glucose for 8 days
Cells cultured in 5 mM glucose were supplemented with 5 mM glucose daily and several
hours prior to protein harvest to maintain glucose levels. In order to generate a model of
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maximal succination, 3T3-L1 fibroblasts were transduced with a lentivirus containing
either fumarase (Fh) shRNA or scrambled control shRNA as described (Frizzell et al.,
2015). The transduced cells exhibiting Fh knockdown were selected for and maintained
in medium containing 1 μg/mL puromycin for 3 days prior to protein harvesting.
N1E Neuronal Culture:
N1E-115 cells (subclone N1E-115-1 neuroblastoma cells) were obtained from
Sigma (08062511, St. Louis, MO). The cells were grown in non-differentiation medium
(NDM, 90% DMEM (Gibco, Grand Island, NY) with 25 mM glucose, no pyruvate, 25
mM HEPES, 4 mM Glutamine) and 10% Foetal Bovine Serum (Atlanta Biologicals,
Atlanta, GA) in 25 cm2 flasks. When confluent the N1E-115 cells were differentiated into
neurons in the presence of 2% FBS and 1.25% DMSO in DMEM. The differentiation was
confirmed visually by phase contrast microscopy. The cells were treated with x
dimethylfumarate for either 3 or 24 hrs prior to harvesting in 50 mM Tris-HCl-EDTA to
assess thioredoxin reductase activity.
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